ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO250

Associations of Hemoglobin Levels and Quality of Life in Patients with CKD: Pooled Results from Three International Surveys

Session Information

Category: Anemia and Iron Metabolism

  • 202 Anemia and Iron Metabolism: Clinical

Authors

  • Jackson, James, Adelphi Real World, Macclesfield, United Kingdom
  • van Haalen, Heleen, AstraZeneca, Gothenburg, Sweden
  • Salehi, Hanna, Adelphi Real World, Macclesfield, United Kingdom
  • Milligan, Gary R., Adelphi Real World, Macclesfield, United Kingdom
  • Moon, Rebecca, Adelphi Real World, Macclesfield, United Kingdom
Background

Anemia is a common comorbidity in patients with chronic kidney disease (CKD), which can affect patients’ quality of life (QoL). The current study aims to determine the burden of anemia in CKD, by analyzing patients' QoL by CKD stage and hemoglobin (Hb) levels.

Methods

Data were drawn from the 2012, 2015 & 2018 Adelphi CKD Disease Specific Programmes. The real-world, point in time surveys included data from physicians and a random sample of their CKD patients across France, Germany, Italy, Spain, United Kingdom (EU5), USA and China. Data were pooled to create a large cross-sectional dataset. Patient demographics, disease characteristics and concomitant conditions were provided by the physicians. Patients completed the Kidney Disease Quality of Life Instrument (KDQOL), including the short form 12 (SF-12), and the EuroQol Visual Analog Scale (EQ VAS). Multivariable analyses were performed on SF-12 and EQ VAS scores, adjusting for age, sex, CKD stage, common comorbidities and CV risk.

Results

KDQOL and EQ VAS results were available for 2781 and 2789 NDD patients and 1749-1726 DD patients, respectively. As CKD stage increased, patients’ QoL deteriorated across all KDQOL domains. In the total population, lower Hb levels were associated with lower KDQOL and EQ VAS scores (Table). This association was also apparent within CKD stages. Adjusted analyses showed statistically significant positive associations between Hb level and the SF-12 physical and mental summary scales as well as EQ VAS scores (all p<0.001), which were numerically strongest in patients not on dialysis.

Conclusion

This study revealed a consistent relation between lower Hb level and deteriorated QoL, which was significant when adjusted for potential confounding factors. Anemia should be recognized as a contributing factor to lower QoL in patients with CKD.

Funding

  • Commercial Support